Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC
Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
Combination immunotherapy and chemotherapy improves progression-free survival for patients with metastatic dMMR colorectal cancer - EurekAlert!
Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer - EurekAlert!
Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer - EurekAlert!
Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC - EurekAlert!
Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC - EurekAlert!
Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!
Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!
COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC - EurekAlert!
Alliance trial shows dual immunotherapy improves progression-free survival in advanced squamous cell skin cancer - EurekAlert!
